samedan logo
 
 
 
spacer
home > ebr > autumn 2019 > the next-generation purification of monoclonal antibodies
PUBLICATIONS
European Biopharmaceutical Review

The Next-Generation Purification of Monoclonal Antibodies




There is unprecedented pressure on the biopharmaceutical industry to improve the performance of monoclonal antibody (mAb) development and manufacturing processes. There are several factors essential to addressing this challenge, including flexibility (in which product changeover time is reduced), quality (as defined by increased robustness and reliability), speed (in which production and product release are accelerated), and cost reductions in manufacturing and capital expenditure.

Improvements in processes and productivity can enable smaller and simpler facilities and lower costs, leading to several advantages, including the ability to:

• Improve competitiveness and long-term sustainability
• Enable business models for new biologics and novel therapies
• Supply developing countries with affordable biologics
• Reach emerging markets profitably

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Gary Skarja is the Head of Membrane Chromatography R&D at Merck. He has 20 years of experience leading dynamic R&D teams in a variety of life sciences sectors, including biopharma, medical device, and cell and gene therapy. Gary holds over 20 patents related to novel polymers, devices, and processes for life sciences applications. He has Bachelor’s and Master’s Degrees in Chemical Engineering from McMaster University, Canada, and a PhD in Chemical Engineering from the University of Toronto, Canada.
spacer
Gary Skarja
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Europital launches as a science-driven full service CRO

Europital – a globally-focused full service CRO serving small and mid-tier innovators – announces a significant expansion as it launches new capabilities across project management, clinical monitoring, biostatistics, pharmacovigilance, regulatory affairs and data management, in addition to its existing services of Medical Affairs and Medical Writing.
More info >>

White Papers

Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites

ArisGlobal

ArisGlobal LLC Investigator site personnel are often frustrated with the lack of transparency and communication with their sponsors, leading to significant dissatisfaction and withdrawal from current and future studies. The adoption of investigator portals gives sponsors a platform that fosters collaboration and improves site management. Learn about five key areas of sponsor-investigator site interactions deserving of electronic communication and collaboration. Technology and design aspects are also covered.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement